DelistingMay 22, 2026, 05:01 PM
Ensysce Biosciences Receives Nasdaq Delisting Notice
AI Summary
Ensysce Biosciences, Inc. received a notice from Nasdaq on May 21, 2026, indicating non-compliance with the $2.5 million stockholders' equity requirement as of March 31, 2026. This subjects the company to delisting unless it submits a plan to regain compliance by July 6, 2026. The company intends to submit a timely plan and actively explore options to meet Nasdaq's listing requirements, though there is no assurance of acceptance or successful compliance.
Key Highlights
- Ensysce Biosciences received a delisting notice from Nasdaq on May 21, 2026.
- The non-compliance is due to failing the $2.5 million stockholders' equity requirement as of March 31, 2026.
- The company must submit a plan to regain compliance by July 6, 2026 (within 45 days).
- If the plan is accepted, an extension of up to 180 days from May 21, 2026, may be granted.
- The company plans to submit a timely plan to Nasdaq and explore options to regain compliance.
Price Impact
More from ENSC